Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD/AML diagnosis
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19776 ↗Kurz gefasst
Fallbericht in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Laureano J Kamiya und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Research Division, Institute for Medical Research Alfredo Lanari, School of Medicine, University of Buenos Aires (UBA), Buenos Aires, Arge…. Hauptthemen laut MEDLINE: Core Binding Factor Alpha 2 Subunit, Glycine, Leukemia, Myeloid, Acute, Mutation, Missense. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: Grupo Cooperativo Argentino de Hemostasia y Trombosis (CAHT), National Agency for the Promotion of Science and Technology (ANCyT), Ministero della Salute.
Abstract (Originalsprache)
Correct interpretation of the pathogenicity of germline RUNX1 variants is essential for FPD/AML diagnosis, clinical management and leukaemia surveillance. We report two families with clear FPD/AML phenotypic features harbouring missense variants at RHD critical residue Gly168. Although classified as of unknown significance (VUS) by RUNX1 ‐specific curation guidelines, these variants should rather be considered likely pathogenic, as supported by computational tools, structural modelling and dysregulated platelet expression of RUNX1‐targets, adding Gly168 among amino acids currently recognised as mutational hotspots. Our data could help reduce the number of variants classified as VUS, providing evidence for updating RUNX1 guidelines, thus improving FPD/AML diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Research Division, Institute for Medical Research Alfredo Lanari, School of Medicine, University of Buenos Aires (UBA), Buenos Aires, Argentina.
- Medical Department, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
- IRCCS University Hospital of Bologna, Bologna, Italy.
- Laboratory of Molecular and Cellular Therapy, Leloir Institute-Institute for Biochemical Research of Buenos Aires (IIBBA), Buenos Aires, Argentina.
- Translational Medicine Research Institute (IIMT), Austral University, Buenos Aires, Argentina.
- Institute for Medical Research (IDIM), UBA-National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
ORCID-Profile: Laureano J Kamiya, Serena Barozzi, Federica Isidori, Daiana Ganiewich, Geraldine De Luca, Valeria Bozzi, Rosana F Marta, Federica Melazzini, Tommaso Pippucci, Paula G Heller, Ana C Glembotsky, Alessandro Pecci
Förderung
- Grupo Cooperativo Argentino de Hemostasia y Trombosis (CAHT)
- National Agency for the Promotion of Science and Technology (ANCyT)
- Ministero della Salute
- Fondation Nelia et Amadeo Barletta
- Fondazione IRCCS Policlinico San Matteo
- Fondo para la Investigación Científica y Tecnológica
Zitieren
APA
Kamiya, L. J., Barozzi, S., Isidori, F., Ganiewich, D., De Luca, G., Bozzi, V., Marta, R. F., Melazzini, F., Pippucci, T., Heller, P. G., Glembotsky, A. C., & Pecci, A. (2024). Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD/AML diagnosis. British Journal of Haematology. https://doi.org/10.1111/bjh.19776
Vancouver
Kamiya LJ, Barozzi S, Isidori F, Ganiewich D, De Luca G, Bozzi V, et al. Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD/AML diagnosis. British Journal of Haematology. 2024. doi:10.1111/bjh.19776
BibTeX
@article{Kamiya2024,
author = {Kamiya, Laureano J and Barozzi, Serena and Isidori, Federica and Ganiewich, Daiana and De Luca, Geraldine and Bozzi, Valeria and Marta, Rosana F and Melazzini, Federica and Pippucci, Tommaso and Heller, Paula G and Glembotsky, Ana C and Pecci, Alessandro},
title = {Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD/AML diagnosis},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19776}
}
EUVIMED